Featured News
March 12, 2026
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
February 25, 2026
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
Our Commitment to Responsibility
At Alkermes, we are committed to making a difference not only in the lives of people living with complex psychiatric and neurological disorders, but also in the communities in which we live and work. We seek to operate our business ethically and grow our organization in a responsible and sustainable manner. Our most recent Corporate Responsibility Report details our efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
World Sleep Day 2026: Sleep Well, Live Better
Michael Doane’s patient interview research deepens our understanding of the depth and breadth of the impact of narcolepsy and IH.
Honoring Caregivers of People Living with Schizophrenia
Jim McGrory reflects on results of a survey about caring for loved ones living with schizophrenia.
Alkermes Pathways Research Awards: Seven Years of Impact
Learn about the impact of the Pathways Research Awards program.
Media Resources
Company Description
Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex, chronic psychiatric and neurological disorders. A global biopharmaceutical company headquartered in Dublin, Ireland, with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of important new medicines in areas which are often overlooked, including addiction, serious mental illness and sleep disorders.
Follow us on our social channels
